These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 4846488)

  • 1. Quantitative studies on tumor enhancement in mice. I. Enhancement of sarcoma I induced by IgM, IgG1, and IgG2.
    Rubinstein P; Decary F; Streun EW
    J Exp Med; 1974 Aug; 140(2):591-6. PubMed ID: 4846488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological enhancement of a murine tumor allograft by passive alloantibody IgG and F(ab')2.
    Kaliss N; Sinclair NR; Cantrell JL
    Eur J Immunol; 1976 Jan; 6(1):38-42. PubMed ID: 971718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune status of mice tolerant of living cells. II. Continuous presence and nature of facilitation-enhancing antibodies in tolerant animals.
    Voisin GA; Kinsky RG; Duc HT
    J Exp Med; 1972 May; 135(5):1185-203. PubMed ID: 4623319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte-antibody interactions in immunological enhancement.
    Takasugi M; Hildemann WH
    Transplant Proc; 1969 Mar; 1(1):530-4. PubMed ID: 5406837
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of placental extracts on the immune response to histocompatibility antigens: class deviation of alloantibody response and allograft enhancement.
    Gupta GS; Kinsky RG; Duc HT; Voisin GA
    Am J Reprod Immunol (1980); 1984; 6(3):117-23. PubMed ID: 6517178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic properties of transplantation immune sera. IV. Influence of the course of immunization, dilution and complexing to antigen on enhancing activity of Ig classes.
    Duc HT; Kinsky RG; Kanellopoulos J; Voisin GA
    J Immunol; 1975 Oct; 115(4):1143-50. PubMed ID: 1176768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between tolerance and facilitation of allografted cells.
    Voisin GA; Kinsky R; Duc HT
    Transplant Proc; 1972 Sep; 4(3):377-82. PubMed ID: 4562765
    [No Abstract]   [Full Text] [Related]  

  • 8. Cellular and humoral immune responses of mice during immunological enhancement of an allogeneic tumor.
    Giorgi JV; Tokuda S; Goldberg EH; Shen FW
    Transplantation; 1978 Mar; 25(3):152-7. PubMed ID: 644650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of radiolabeled alloantibodies in mice bearing 3-methylcholanthrene-induced sarcoma.
    Buchsbaum DJ; Walker PC; Johnson EA
    Cancer Res; 1979 Sep; 39(9):3363-8. PubMed ID: 476667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of growth of allogeneic mouse tumor by the IgG1 fraction of alloantibody preparations.
    Harris TN; Harris S; Henri EM; Farber MB
    J Natl Cancer Inst; 1978 Jan; 60(1):167-72. PubMed ID: 628014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative studies on bovine immunoglobulins, normal plasma levels of IgG2, IgG1, IgM and IgA.
    Williams MR; Maxwell DA; Spooner RL
    Res Vet Sci; 1975 May; 18(3):314-21. PubMed ID: 806944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-mediated suppression of grafted lymphoma. III. Evaluation of the role of thymic function, non-thymus-derived lymphocytes, macrophages, platelets, and polymorphonuclear leukocytes in syngeneic and allogeneic hosts.
    Shin HS; Hayden M; Langley S; Kaliss N; Smith MR
    J Immunol; 1975 Apr; 114(4):1255-63. PubMed ID: 1078832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of tumor-specific enhancement versus resistance toward a methylcholanthrene-induced murine sarcoma.
    Bloom ET; Hildemann WH
    Transplantation; 1970 Oct; 10(4):321-33. PubMed ID: 4927387
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunochemical and biologic characterization of alloantibody active in immunologic enhancement.
    Fuller TC; Winn HJ
    Transplant Proc; 1973 Mar; 5(1):585-7. PubMed ID: 4695953
    [No Abstract]   [Full Text] [Related]  

  • 15. Suppression of immunoglobulin class synthesis in mice. I. Effects of treatment with antibody to -chain.
    Lawton AR; Asofsky R; Hylton MB; Cooper MD
    J Exp Med; 1972 Feb; 135(2):277-97. PubMed ID: 4551216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of the amplified enzyme-linked immunosorbent assay: comparative quantitation of bovine serum IgG1, IgG2, IgA, and IgM antibodies.
    Butler JE; McGivern PL; Cantarero LA; Peterson L
    Am J Vet Res; 1980 Sep; 41(9):1479-91. PubMed ID: 7004283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Passive allograft enhancement by subclasses of polyclonal antibodies directed toward restricted regions of the major histocompatibility complex.
    Duc HT; Kinsky RG; Voisin GA
    Transplantation; 1982 May; 33(5):492-9. PubMed ID: 6806954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune inhibition of allogeneic lymphoma cells in the peritoneal cavity of mice.
    Fioretti MC; Libarati M; Bonmassar E; Cudkowicz G
    Cancer Res; 1975 Jan; 35(1):30-6. PubMed ID: 1089042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-mediated suppression of tumor growth. I. Suppression by murine IgG1 isolated from alloantiserum.
    Johnson RJ; Pasternack GR; Shin HS
    J Immunol; 1977 Feb; 118(2):489-93. PubMed ID: 851484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic enhancement of sarcoma I by mouse gamma-globulin fractions.
    Tokuda S; McEntee F
    Transplantation; 1967 Jul; 5(4):606-14. PubMed ID: 6050317
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.